Drug intelligence / Profile preview

ARVN006

Development stage: Preclinical
Lead developer: Arctic Vision
Modality: Small Molecules
Administration: Oral

Overview

ARVN006 is an orally administered small molecule chemical drug being developed by Arctic Vision for the treatment of retinopathy, including diabetic retinopathy (DR) and diabetic macular edema (DME). Unlike anti-VEGF therapies, ARVN006 acts on an innovative, undisclosed target to provide neuroprotective and therapeutic effects directly within the retina while maintaining systemic safety. The drug is currently in preclinical development.

Beyond the preview

Go deeper on ARVN006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ARVN006.

Explore the full profile